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JC virus (JCV) is a common human polyomavirus that infects greater than 70% of the general population worldwide. JCV
is also the causative agent of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the CNS.
Currently, little is known about the mechanisms that restrict JCV tropism to a few human cell types and tissues. In vivo, JCV
can be detected in oligodendrocytes and astrocytes in the CNS of patients with PML. The virus can also be detected in
kidney, tonsil, and B lymphocytes of patients both with and without PML. In vitro, JCV can only be propagated in cultures of
human fetal glial cells or in cell lines derived from this tissue. In contrast, the closely related monkey polyomavirus, SV40,
has a broad tropism for primate cells, including those cells that are also susceptible to infection by JCV. We hypothesized that
one potential block to infection is at the level of virus entry. To examine this, we constructed a JCV-SV40 chimeric viral
genome that contains the regulatory region and the early genes of SV40 and the late structural genes of JCV. The hybrid virus
(JCSV) induced SV40-like cytopathic effect in human glial cells and hemagglutinated human type O red blood cells similar to
JCV. More importantly, the hybrid virus maintained the host range of JCV, suggesting that interactions between the virusINTRODUCTION
The human polyomavirus JC virus (JCV) is the caus-
ative agent of the fatal demyelinating disease progres-
sive multifocal leukoencephalopathy (PML). Seroepide-
miological studies have shown that greater than 70% of
the human population worldwide is infected by JCV, with
seroconversion typically occurring in early childhood
(Padgett and Walker, 1973). Affecting mainly immuno-
compromised patients, PML was formerly considered a
rare disease; however, the frequency of disease has
dramatically risen in association with increasing HIV
infection. It is estimated that 85% of PML cases have
AIDS as the underlying immune deficit and that 2–4% of
AIDS patients will develop this rapidly fatal, opportunistic
disease (Berger and Concha, 1995). There is currently no
effective treatment for PML, although highly active anti-
retroviral therapy (HAART) has been shown to improve
symptoms of PML in some patients (Clifford et al., 1999).
PML develops from lytic infection of myelin-producing
oligodendrocytes in the CNS. In vivo, JCV can also be
found in B cells in lymphoid organs and it has been
hypothesized that these tissues may be a reservoir of
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282latent JCV genomes and that B cells may traffic JCV to the
CNS (Major et al., 1992; Monaco et al., 1996, 1998; Tor-
natore et al., 1992; Wei et al., 2000). In vitro, the tropism
of JCV is restricted to human glial cells and to a limited
extent, human B cell lines. In our laboratory we use the
SV40 T antigen transformed SVG-A cell line to propagate
JCV. This cell line was derived by limited dilution cloning
of the parental SVG cell line described by Major et al.
(1985). SVG-A cells support JCV infection and replication
in vitro to levels comparable to primary human fetal glial
cells.
The mechanisms restricting the tropism of JCV to
these few cell types is not known. SV40, in comparison,
can infect a broad range of cells of primate origin, in-
cluding human and monkey cell lines such as SVG-A
(human fetal glial), CV-1 (monkey kidney), and BSC-1
(monkey kidney) (Tooze, 1973). The broad tropism of
SV40 is consistent with the fact that SV40 utilizes the
ubiquitously expressed major histocompatibility complex
(MHC) class I protein as a receptor for virus entry (At-
wood and Norkin, 1989; Breau et al., 1992; Stang et al.,
1997). In contrast, JCV does not use MHC class I proteins
as a receptor but rather uses an N-linked glycoprotein
containing  2–6 linked sialic acid as one component of
its receptor (Liu et al., 1998). The proteinaceous compo-
nent of the receptor has not been identified.capsid and host cell receptors contribute to JCV tropism.
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To assess the contribution of viral structural proteins
to host cell tropism, we constructed a novel JCV/SV40© 2002
recept
chimeric virus (JCSV) containing the regulatory and early
regions of SV40 and the late capsid coding region of JCV.
We asked whether this chimeric virus would maintain the
host range of JCV or whether its host range would be
expanded to cells that are susceptible to SV40 infection
but not to JCV infection. The chimeric virus displayed
physical and biological properties of both SV40 and JCV
but maintained the host range of JCV. These data clearly
demonstrate that early events in the life cycle of JCV
contribute to virus tropism.
RESULTS
Production of infectious virus from the chimeric
genome
To determine the contribution of the viral coat proteins
of JCV to the host cell tropism of this virus, we exchanged
the late region of SV40 for that of JCV (Fig. 1). Once the
chimeric viral genome was constructed, we separated
the viral DNA from plasmid sequences by digesting with
BamHI and gel purifying the viral genome fragment. This
linear DNA (10 g) fragment was then transfected into
SVG-A cells (8  106 cells/75 cm2 flask) by calcium
phosphate-mediated transfection. To determine whether
the viral genome was being expressed, the transfected
cells were plated onto coverslips in six-well dishes. One
week posttransfection, the cells were fixed and stained
for VP1 expression with the monoclonal antibody
PAB597. Immunofluorescent detection revealed V anti-
gen expression, indicating transcription of the hybrid
genome (Fig. 2, pJCSV-2.5.1).
To demonstrate that infectious virions were being pro-
duced, lysates of the transfected cells were used to
infect fresh SVG-A cells. Positive staining for V antigen
was observed, indicating that viable, infectious virus was
present, hereafter referred to as JCSV (Fig. 2, JCSV).
Infection of SVG-A cells was blocked by anti-JCV anti-
sera, indicating that the source of infectious material in
the lysate was virus and not viral DNA (not shown).
Biological characterization of JCSV
We compared the cytopathic effects induced in SVG-A
cells by infection with equivalent amounts of SV40, JCSV,
and JCV (Mad-1 SVE). Note that SV40 is known to
induce extensive cytoplasmic vacuolization in infected
cells. In contrast, infection of cells with JCV induces a
necrotic phenotype that takes several weeks to develop.
Interestingly, the cytopathic effect (CPE) induced by in-
fection of SVG-A cells by the hybrid virus, JCSV, was
similar to SV40-induced CPE (Fig. 3, compare A and C).
Infection of SVG-A cells with the Mad-1SVE strain of
JCV induced the expected necrotic phenotype (Fig. 3B).
We next compared the abilities of JCSV, JCV (Mad-1
SVE), and SV40 to hemagglutinate human type O red
blood cells. Both JCSV and JCV (Mad-1 SVE) hemag-
glutinated red blood cells in a dose-dependent manner
(Fig. 3). As expected, SV40 did not hemagglutinate hu-
man type O red blood cells (Fig. 3).
Infection of SVG-A, CV-1, and COS-7 cells with SV40,
JCSV, and JCV (Mad-1SVE)
The SVG-A cell line was derived from primary human
fetal glial cells transformed by origin-defective SV40.
SVG-A cells are permissive to both JCV and SV40 infec-
tion. CV-1 cells, an African monkey kidney cell line, are
permissive for the lytic growth of SV40 but are nonper-
missive for JCV infection. As COS-7 cells are also trans-
formed with SV40 T antigen, we used them to control for
any effects that SV40 T antigen expression might have on
JCV tropism. Note that COS-7 cells have been reported to
have low level susceptibility to JCV (Hara et al., 1998).
SVG-A, CV-1, and COS-7 cells were plated in six-well
dishes and infected with 25 HAU of JCSV, JCV (Mad-1
SVE), or with 1.2  106 PFU of SV40, and scored for
either T-antigen (CV1) or V-antigen (SVG-A and COS-7)
expression at 3 days postinfection. SVG-A cells were
efficiently infected by SV40, JCSV, and JCV (Mad-1 SVE)
(Fig. 4). The results show that equivalent amounts of
JCSV and JCV (Mad-1 SVE) led to comparable levels of
infection in SVG-A cells, 32 and 40%, respectively (Fig. 4).
In contrast, CV-1 and COS-7 cells were not efficiently
infected by either JCV or JCSV (Fig. 4). As expected, they
were highly susceptible to infection with SV40 (Fig. 4).
To determine whether the reduced efficiency of JCSV
infection of CV-1 and COS-7 cells was due to a block at
entry or at a postentry step, we transfected the cells with
DNA isolated from SV40, JCSV, and JCV (Mad-1 SVE)
virions. At three days posttransfection the cells were
fixed and assayed for T antigen (CV1) or V antigen
(COS-7) expression. Transfection of CV1 cells with DNA
from each of the three viruses led to T antigen expres-
sion in a minority of the cells (Fig. 5). The percentage of
cells expressing T antigen following transfection was
consistent with the poor transfection efficiencies mea-
sured in these cells (not shown). In contrast to CV1 cells
transfection efficiency in COS-7 cells is very high. Trans-
fection of these cells with each of the three viral DNAs
led to high levels of viral antigen expression (Fig. 5).
Although it is difficult to make definitive conclusions
regarding the susceptibility of CV1 cells to infection with
virus or viral DNA due to poor transfection efficiency, the
results in COS-7 cells clearly demonstrate that a major
block to infection in COS-7 cells is at the level of viral
entry as JCV and JCSV viral DNA but not virions led to
efficient viral gene expression in these cells.
DISCUSSION
The ability to generate pseudotyped and chimeric viral
genomes has played a major role in allowing us to
understand how early events, such as host cell receptor
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recognition, contribute to viral tropism. The human poly-
omavirus, JCV, has a very restricted cell tropism which is
due in part to molecular events downstream of viral entry
(Feigenbaum et al., 1987; Raj and Khalili, 1995; Sumner et
al., 1996; Tornatore et al., 1994; Vacante et al., 1989). The
generation of chimeric viral genomes has helped to elu-
cidate some of these properties. For example, early work
swapping the regulatory and T antigen coding regions of
FIG. 1. Construction of a chimeric JCV-SV40 genome (JCSV). The chimeric genome was created by exchanging the SV40 late region with that of
JCV. The late region proteins include Agnoprotein, VP1, VP2, and VP3. (A) PCR amplification of JCV late region DNA from the Mad-1 SVE strain of
JCV and ligation into pGEM-T vector. (B) Restriction digest and ligation of the late region of JCV from pGEM-T into the SV40 plasmid, pBRSV to create
pBRSVJC2.5.1. (C) Restriction digest of pBRSVJC2.5.1 to release the hybrid viral genome from the plasmid backbone. See Materials and Methods for
details of the cloning strategy.
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JCV and SV40 found that the host range of JCV was not
expanded by the substitution of SV40 regulatory ele-
ments into a JCV backbone (Chuke et al., 1986). SV40
DNA containing JCV regulatory sequences, however,
were able to replicate in CV-1 cells and produce lytically
active virus upon transfection. This indicated that SV40
large T antigen could efficiently interact with the JCV
transcription signals but that the JCV T antigen was not
fully capable of interacting with SV40 regulatory signals.
The Mad-1 SVE strain of JCV was originally devel-
oped to address the role of the regulatory region in
restricting virus tropism (Vacante et al., 1989). The virus
was constructed by inserting the entire SV40 regulatory
region into the JCV Mad-1 backbone. Following transfec-
tion of this hybrid DNA into glial cells, a virus emerged
that had deleted portions of both the SV40 and the JCV
regulatory region. This chimeric virus was found to have
expanded its host range to human embryonic kidney
cells and to both fetal and adult rhesus monkey glial
cells (Vacante et al., 1989). The chimeric virus did not
infect the WI-38 line of human diploid lung fibroblasts or
the BSC-1 line of African green monkey kidney cells,
indicating that either the hybrid regulatory region was
not permissive in these cell types or the virus failed to
enter these cells (Vacante et al., 1989).
We have made extensive use of the Mad-1 SVE strain
of JCV to characterize the early events of JCV infection,
including virus–host cell receptor interactions (Liu et al.,
1998; Pho et al., 2000; Wei et al., 2000). However, as the
virus has a hybrid regulatory region and is still restricted
for infection of some cell types, it has not been possible
to completely dissect contributions to tropism made by
the capsid from contributions made by the regulatory
elements. To address this, we constructed a novel virus
by inserting the entire late region of JCV into the SV40
backbone. Sequencing was performed at each step dur-
FIG. 2. Expression and production of JCSV by transfection of SVG-A cells. SVG-A cells were either mock transfected or transfected with 10 g of
pJCSV-2.5.1 DNA excised from the plasmid pBRJCSV-2.5.1 (as indicated). At 1 week posttransfection cells were plated onto coverslips, fixed in acetone,
and assayed for the V antigen expression by indirect immunofluorescence assay. Lysates of these transfected cells (JCSV) were then used to infect
SVG-A cells. At 3 days postinfection the cells were assayed for V antigen expression.
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ing the construction of this virus to be sure that we were
not introducing additional, unexpected mutations and
alterations in the hybrid genome. Once the virus was
constructed, we asked whether it would maintain the
host range of JCV or whether its host range would be
expanded to those cells that are also susceptible to SV40
infection. Our initial characterization of the virus revealed
that JCSV had a true hybrid phenotype. Infection of
SVG-A cells with JCSV led to SV40-like CPE, a charac-
teristic that is not shared by either wild-type Mad-1 or
Mad-1SVE. Similar to JCV, however, the hybrid was
capable of hemagglutinating red blood cells. When
SVG-A, CV-1, and COS-7 cells were challenged with JCSV
only, SVG-A cells were efficiently infected. In contrast,
each of these cell types expressed viral antigens follow-
ing transfection with viral DNA. Our results do not differ
significantly from a recent report demonstrating infection
of a wide variety of cell types by JCV (Suzuki et al., 2001).
This report used a highly sensitive PCR-based approach
to demonstrate that input viral DNA could be amplified
from nuclear fractions following incubation with JCV. As
the percentages of infected cells were not documented
in this report, it is likely that the positive PCR results
derive from a minority of cells that did become infected.
FIG. 3. Biological characterization of JCSV. SVG-A cells were infected with either JCSV (A), the Mad-1 SVE strain of JCV (B), or with SV40 (C). The
cultures were monitored weekly for signs of cytopathic effect (CPE). SVG-A cells infected with either JCSV or SV40 developed extensive CPE with SV40
similar to vacuolization of the cytoplasm within 5 days postinfection (A and C, arrows). In contrast, SVG-A cells infected with JCV (Mad-1 SVE)
developed CPE with a necrotic phenotype by 2 weeks postinfection, which is characteristic of JCV infection (B). Hemagglutination assay. Twofold
serial dilutions of JCSV, JCV (M1-SVE), or SV40 in PBS were made in 96-well dishes and a 0.5% suspension of human type O red blood cells was
added. Following incubation at 4°C for 2 h, hemagglutination activity was scored. JCSV had a hemagglutination titer of 128 HAU/50l and JCV
(M1-SVE) had a hemagglutination titer of 4096HAU/50 l. SV40 does not hemagglutinate. Control  no virus added.
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We also observe low levels of infectivity in both CV1 and
COS-7 cells (typically 1–3%). This low level of infectivity
could be due to either low level expression of JCV re-
ceptors on CV-1 and COS-7 cells or entry by an alterna-
tive less efficient mechanism. We are currently exploring
these possibilities. This new hybrid virus will be an
invaluable tool for dissecting the role that receptors and
other early events play in determining the tropism of this
important human polyomavirus.
MATERIALS AND METHODS
Cells, viruses, and antibodies
SVG-A (SV40 transformed human fetal glial cell line),
CV-1 (African green monkey kidney cell line), and COS-7
(SV40 transformed CV1) cells were propagated in Eagle’s
minimum essential medium (EMEM, Mediatech) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS, Mediatech) and 1% penicillin/streptomycin (P/S,
HyClone) (complete media). Cells were maintained as a
monolayer at 37°C in a humidified atmosphere of 5%
CO2.
The Mad-1 SVE (M1-SVE) strain of JCV and the
wild-type 777 strain of SV40 were used in these experi-
ments. M1-SVE is a hybrid strain of JCV described
previously that contains portions of the SV40 regulatory
region (Vacante et al., 1989). The remaining genome is
contributed completely by the Mad-1 strain of JCV. Viral
DNA from both viruses were obtained by lysing CsCl2-
purified virus in 1% SDS followed by phenol/chloroform
extraction and ethanol precipitation. The numbering sys-
tems used for the JCV and SV40 genomes are those
established by Frisque and Fiers, respectively (Fiers et
al., 1978; Frisque et al., 1984).
For immunodetection of V antigen, PAB597, a mouse
monoclonal antibody raised against SV40 V-antigen that
cross-reacts with JCV, was used. A mouse monoclonal
antibody against SV40 T antigen (Calbiochem) was used
to detect SV40 T antigen expression in CV-1 cells. T
antigen expression was not assessed in SVG-A or COS-7
cells because these cells constitutively express SV40 T
antigen as a result of SV40 transformation. Goat anti-
mouse IgG conjugated to fluorescein isothiocyanate
(GM-FITC) was used as a secondary antibody to detect
positive expression of V or T antigens.
Construction of JCV-SV40 chimeric genome
To construct the JCV-SV40 hybrid genome, the late
region of JCV was cloned by PCR and used to replace the
SV40 late region, as shown in Fig. 1. Briefly, the late
region of JCV was PCR amplified using primers JCV275-
Kpn and JCV2533-Bam/Sal. JCV275-Kpn contains an en-
gineered KpnI site at the 5 end placed 2 bp upstream of
the start of Ag. JCV2533-Bam/Sal contains adjacent en-
gineered BamHI and SalI sites at the 3 end directly
following the stop codon of VP1. The template for PCR
was M1-SVE viral DNA. PCR was performed with 0.2 g
template, 6 mM MgSO4, 1.5 mM dNTPs, 1 g of each
primer, and 1.25 U Platinum Pfx DNA polymerase (Gibco-
BRL), using the following protocol: 94°C 2 min, then 95°C
15 s, 50°C 30 s, 72°C 3 min for 30 cycles, followed by a
final 72°C extension for 7 min. The PCR fragment was
then A-tailed and subcloned into the T-tailed cloning
vector pGEM-T (Promega). DNA was isolated from po-
tential positive clones using the QIAprep Spin Miniprep
Kit (Qiagen) and analyzed for insert by restriction digest
using KpnI and SalI. Inserts from positive clones were
then completely sequenced in both directions to ensure
that no mutations had been introduced by the polymer-
ase. In one clone, pGEMJC(Vp)-2.5, no errors were found
except for loss of the SalI site in the insert. This error
could be compensated for by using the SalI site in the
pGEM-T vector. pGEMJC(Vp)-2.5 was used to construct
the chimeric genome.
DNA transfection
All transfections were done by calcium phosphate-
mediated transfection. Cells were seeded so that they
reached a density of approximately 70% confluence prior
to transfection. For a 75-cm2 flask of cells, viral DNA was
added to 2.0 ml HEPES buffer followed by the addition of
125 l of 2 M CaCl2. For six-well dishes, 200 l HEPES
buffer and 12.5 l 2 M CaCl2 were used. The mixture was
then added directly to cells washed with HEPES buffer
and incubated at room temperature for 20 min with oc-
casional rocking. Complete media were then added to
the cells and incubated at 37°C in a 5% CO2 humidified
atmosphere for 4 h. Cells were then rinsed two times
with complete media, allowed to incubate at 37°C, 5%
CO2 in complete media, and monitored for CPE.
Virus infection
Virus infections were carried out under Biosafety Level
2 safety precautions. Cells were seeded so that they
reached a density of approximately 70% confluence prior
to infection. Virus was diluted appropriately in EMEM
supplemented with 2% FBS/1% P/S in a volume sufficient
to cover the cells. Virus was allowed to adhere to cells
for 1 h at 37°C, 5% CO2 with occasional rocking. Com-
plete media were then added and the infected cells were
incubated at 37°C, 5% CO2 in a humidified incubator.
Virus stock preparation
Twenty 175-cm2 tissue culture flasks were seeded
with SVG-A cells at a density of approximately 50% con-
fluence prior to infection. Virus inoculum was prepared
by diluting the virus 1:50 in EMEM/2% FBS/1% P/S in a
volume of 5 ml per flask. Media were aspirated from the
cells followed by addition of virus inoculum directly to the
cells for 1 h at 37°C, 5% CO2 with occasional rocking.
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Complete media (25 ml) were then added to the culture
and incubated at 37°C, 5% CO2 in a humidified atmo-
sphere. Media were replaced once a week by aspirating
old media and adding 25 ml of fresh complete media.
When significant CPE was observed, cells were har-
vested by scraping cells off the flask and pelleting at
FIG. 4. Infection of SVG-A, CV-1, and COS-7 cells with SV40, JCSV, and JCV (Mad-1SVE). SVG-A, CV-1, and COS-7 cells were infected with 25 HAU
of JCSV, JCV (Mad-1 SVE), or with 1.2 106 PFU of SV40. Cells were scored at 3 days postinfection for V-antigen expression (SVG-A and COS-7 cells)
or T antigen expression (CV-1 cells) by indirect immunofluorescent assay. The percentage of infected cells is indicated. JCSV and JCV (Mad-1 SVE)
infected SVG-A cells with similar efficiency. JCSV also infected CV-1 and COS-7 cells but at much reduced efficiency when compared to infection of
SVG-A cells (32% vs 1% for CV1 and 3% for COS-7). JCV (Mad-1 SVE) did not infect CV-1 cells but did infect COS-7 cells, again with reduced efficiency
(32% vs 2%). SV40 infected all three cell types efficiently. Magnification, 100.
FIG. 5. Transfection of CV-1 and COS-7 cells with viral DNA. CV-1 and COS-7 cells were transfected with 1.5 g of SV40, JCSV, or JCV (Mad-1SVE)
viral DNA and scored for T antigen (CV1) or V antigen (COS-7) expression at 3 days posttransfection. The percentage of T or V antigen expressing
cells is indicated. Magnification, 100.
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3000 g for 20 min at 4°C. The pellet was then suspended
in 1/10 the volume of supernatant. The remaining super-
natant was discarded since virus remains highly cell-
associated. The cells were subjected to three freeze-
thaw cycles (80°C to 37°C) with vortexing. Deoxy-
cholate was then added to a final concentration of 0.25%
(v/v) and incubated at 37°C for 30 min to release virus.
Cellular debris was pelleted by centrifugation at 12,000 g
for 30 min at 4°C. The virus-containing supernatant was
saved, aliquoted, and stored at 80°C.
Virus was concentrated by centrifugation through a
20% sucrose solution in Buffer A (10 mM Tris–HCl pH 8.0,
50 mM NaCl, 0.01 mM CaCl2, 1% Triton X-100) at 35,000
rpm, 15°C for 3 h. The pellet was then resuspended in
Buffer A and centrifuged through a premade CsCl step
gradient (1.35, 1.32, 1.29, 1.26, 1.23 g/ml) at 35,000 rpm,
15°C overnight. The virus band was removed and dia-
lyzed against Buffer A without Triton X-100 overnight at
4°C.
Viral DNA was isolated by lysing the CsCl-purified
virus in 1% SDS at 50°C for 1 h followed by 2 phenol
extraction, 2 phenol/chloroform extraction, 1 chloro-
form extraction, and ethanol precipitation.
Hemagglutination assay
Human type O red blood cells (RBC) were diluted to
0.5% in Alsever’s solution (0.1 M D-glucose, 0.027 M
sodium citrate, 0.07 M NaCl, pH 6.5) and used in the HA
reaction as previously described (Liu and Atwood, 2001).
Briefly, twofold dilutions of each virus to be titered were
made in 96-well U-bottomed dishes. A 50 l of suspen-
sion of RBCs was then added to each well and the plates
were incubated at 4°C for 2–4 h. The last dilution to fully
hemagglutinate RBCs was used to determine the titer of
the virus.
Indirect immunofluorescence assay
Cells were seeded onto glass coverslips in six-well
tissue culture dishes so that they reached a density of
approximately 70% confluence. Cells were then infected
as described, using an appropriate dilution of virus in a
volume of 100 l. Three days postinfection, the media
were aspirated and cells were washed two times in
phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl,
4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.2; PBS). Cells
were then permeabilized and fixed to coverslips in ice-
cold acetone for 10 min and allowed to air dry. Cells were
probed with primary antibody (PAB597, undiluted, or
mouse SV40-T, diluted 1:50 in PBS) for 30 min at 37°C,
washed two times with PBS, and probed with the sec-
ondary antibody goat  mouse-FITC (diluted 1:50 in PBS)
for an additional 30 min at 37°C. Coverslips were then
washed two times with PBS, counterstained with Evans
blue, washed two times with PBS, and mounted onto
slides with 90% glycerol in PBS. Stained cells were visu-
alized under a Zeiss epifluorescence microscope.
Sequencing and primers
All sequencing was performed by the Brown University
Sequencing Core Facility. Sequencing reactions con-
tained 0.5 g of DNA and 3.2 pmol primer in a volume of
10 l of water. Primers (Gibco-BRL) were designed
based on the published sequences of the Mad-1 strain of
JCV, strain 777 of SV40, pGEM-T vector, and pBR322
vector. Numbering in primer names indicates the 5 po-
sition of primer. For and Rev (forward and reverse) indi-
cate the direction of sequencing. The primers used in
these experiments are as follows (5 3 3):
JCV275-Kpn: GGTACCCCATGGTTCTTCGCCAGCTGT-
CACGTAA
JCV2533-Bam/Sal: GTCGACGGATCCTTACAGCATTTT-
TGTCTGCAAC
JCV265 For: CACCAGCTGGCCATGGTTCTTCGCC
JCV776 For: GGTTCAAACTGTAACTGGTG
JCV-1369 For: GCACCAGGAGGTGCAAATCAAAG
JCV-1982 For: CCAAAGAATGCCACAGTGCAATC
JCV986 Rev: CCCCAATGTCTAGGATCTAAATAG
JCV-1568 Rev: CCCCAGTTTTAACTTCTAGAAC
JCV2180 Rev: GCAACACTGTTGTGGCAGTG
SV164 For: GGGACTTTCCACACCTGGTTGCTGAC
pGEM2956 For: ACGTTGTAAAACGACGGCCAGTGAA
pGEM140 Rev: TAGGTGACACTATAGAATACTCAAG
pBR762 Rev: CCTACGAGTTGCATGATAAAGAAGAC
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